Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.
about
Pharmacotherapy for stimulant-related disordersDopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humansTreadmill exercise improves fitness and reduces craving and use of cocaine in individuals with concurrent cocaine and tobacco-use disorderEffects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.The α1 Antagonist Doxazosin Alters the Behavioral Effects of Cocaine in RatsTreatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidityEffects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial.Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.Buspirone reduces sexual risk-taking intent but not cocaine self-administration.Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol.Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNODrugs currently in Phase II clinical trials for cocaine addiction.Designing modulators of 5-hydroxytryptamine signaling to treat abuse disorders.Effects of social reorganization on dopamine D2/D3 receptor availability and cocaine self-administration in male cynomolgus monkeys.Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex.Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study.The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity.Remote physiological monitoring of acute cocaine exposure.Pharmacokinetics, tissue distribution, and excretion studies of l-isocorypalmine using ultra high performance liquid chromatography with tandem mass spectrometry.
P2860
Q26829186-2F4CE462-FD4F-4A46-B8A1-CE33C5525A30Q28265851-8A63CACA-082B-43BF-8797-2EBA4AA02221Q28391787-403478B2-FE56-4B41-A790-0F9CF066D5FFQ33750819-2CC6D02C-22C8-4355-BDBF-FBC78B99F292Q33771996-B4F8B9B3-2AAF-45CD-9FCF-3DA06DA0BD17Q33998159-8779E4E6-1501-477D-8C1C-5743333ABA34Q35143914-17492CC1-98C3-4E6F-AF89-40F2CC2D9276Q35200015-18451C61-CFE8-4885-B1B7-404F00D846E6Q35576598-FBEF8873-B810-4F0C-AEB3-ED285EFFDA0DQ35685121-AA5F9CDC-1D5A-40B9-96E8-AB3AEC2EC2A6Q36036175-B8E53921-59CE-45DB-B1B3-E5414679F0A1Q36384712-7B2ADDF4-4854-4FE4-AE1C-C1E2651AE69CQ36650526-C6846598-DA56-409F-B496-DFAC2ADFF7E6Q36976585-E64D49A0-9199-4BC5-95A7-A83D8F7522EDQ37107238-C527C91A-FFB9-4300-8A05-A26EED47254CQ37172714-07355E64-E648-41D4-8E43-A5D72411DC9AQ37409577-3702483D-C22A-4FF9-B8FD-A52AF746E270Q38207705-D0D534BD-5171-459F-9F70-BB9462233774Q38248774-CC81B478-552C-45E8-9ACC-1A0CC0B3C76BQ38728501-0B8CCE02-D65D-44D2-B77E-D3C9F8406CD9Q38845514-E2F8DE0D-D1E4-4F13-B3EB-AE3D3EC92241Q39642220-1C502114-44C0-410D-85AD-266E8EE3D00CQ41845591-DCBD711E-4693-40C4-B6F7-CEF27070F7E3Q45909094-95C9D8A8-8EB3-4A2E-9AE9-18584C7088E4Q47869324-21E9EDC5-27FE-4146-9F39-97D9D398104DQ52311430-E0EC3506-0619-4802-8664-F401FC995B63
P2860
Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@ast
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@en
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@nl
type
label
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@ast
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@en
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@nl
prefLabel
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@ast
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@en
Pharmacotherapeutics directed ...... norepinephrine and glutamate.
@nl
P2093
P2860
P50
P1476
Pharmacotherapeutics directed ...... , norepinephrine and glutamate
@en
P2093
Colin N Haile
James J Mahoney
Richard De La Garza
Thomas F Newton
P2860
P304
P356
10.1016/J.PHARMTHERA.2012.01.010
P577
2012-01-31T00:00:00Z